## EPAM: EPAM Systems, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%); PEG 1.39 fails VALUE criteria (<1.0); RSI 70 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS), overbought RSI (70).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($196.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. EPAM Unveils Enterprise AI Agents on Google Cloud Marketplace**
- Source: MyChesCo | 20251218T130831 | Bullish | Relevance: 100%
- EPAM Systems, Inc. has introduced a collection of production-ready AI agents on Google Cloud Marketplace, deepening its partnership with Google Cloud to drive enterprise adoption of generative and agentic AI. These offerings are designed to be secure, compliant, and rapidly deployable, helping organizations accelerate AI integration and manage cloud costs efficiently. The initial suite includes seven AI agents addressing critical business and industry challenges, ranging from financial services' Know Your Customer solutions to AI-powered clinical document authoring and cloud-based drug discovery pipelines.

**2. Oak Thistle LLC Acquires Shares of 9,863 EPAM Systems, Inc. $EPAM**
- Source: MarketBeat | 20251218T110915 | Bullish | Relevance: 100%
- Oak Thistle LLC has acquired a new stake of 9,863 shares in EPAM Systems, Inc. (NYSE:EPAM) during the third quarter, valued at approximately $1.487 million. Other institutional investors also modified their holdings, with 91.58% of the stock owned by institutional investors. EPAM Systems reported strong Q3 earnings, beating estimates, and authorized a $1.00 billion share buyback program.

**3. The Lab of the Future: Four Strategic Priorities for Near-Term Digital Transformation**
- Source: EPAM | 20251219T170811 | Bullish | Relevance: 100%
- This white paper outlines four strategic priorities for modernizing laboratory operations in the near future: modern data platforms, targeted AI, selective automation, and workforce development. It offers a pragmatic roadmap for pharmaceutical and biotech labs to navigate challenges like data volume and regulatory changes, focusing on practical implementation and scaling across sites. The goal is to amplify human scientists rather than replace them, providing clear actionable steps for digital transformation.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.41M) |
| Sells | 4 ($2.30M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+0.4%)
- Blackrock Inc.: 8.5% (+4.7%)
- Invesco Ltd.: 7.1% (-4.7%)
- Ameriprise Financial: 4.8% (+28.9%)
- State Street Corpora: 4.2% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Overbought RSI (70) with bearish MACD signals exhaustion.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.39 suggests fair value with growth premium. Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.30). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.7B |
| Beta | 1.75 |
| 52W Range | $138.15 - $269.00 |
| Short Interest | 6.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.39 |
| Forward P/E | 16.8 |
| Current P/E | 18.3 |
| YoY Growth | 8.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.0% to 0.3% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.66), momentum weakening. RSI overbought at 70, risk of mean reversion. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.33% (CS: 61) | Neutral |
| RSI_14 | 70.2 | Overbought |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.178x | Above |
| vs SMA200 | 1.235x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $209.27
- **Stop Loss:** $196.87 (5.9% risk)
- **Target:** $221.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 96
- **Position Value:** $20,089.92
- **Portfolio %:** 20.09%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-19 (Est: $3.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.03 | $3.08 | +1.7% |
| 2025Q2 | $2.61 | $2.77 | +6.0% |
| 2025Q1 | $2.27 | $2.41 | +6.1% |
| 2024Q4 | $2.75 | $2.84 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*